News Release

Printer Friendly Version View printer-friendly version << Back
September 10, 2009 at 4:01 PM EDT

Quidel to Present at Investor Conferences in September

SAN DIEGO--(BUSINESS WIRE)--Sep. 10, 2009-- Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, announced today that President and Chief Executive Officer Douglas Bryant will be presenting at the CL King & Associates 7th Annual Best Ideas Conference onThursday, September 17, 2009 and the UBS Global Life Sciences Conference on Monday, September 21, 2009, both in New York City.

  • CL King & Associates 7th Annual Best Ideas Conference
    Thursday, September 17, 2009 at 12:15 p.m. Eastern time (9:15 a.m. Pacific time)
    Omni Berkshire Place Hotel, New York City

    To listen to the presentation via a live audio webcast and view Quidel’s most current investor relations presentation, use the following webpage link:

  • UBS Global Life Sciences Conference
    Monday, September 21, 2009 at 2:00 p.m. Eastern time (11:00 a.m. Pacific time)
    Grand Hyatt, Grand Central in New York City

    To listen to the presentation via a live audio webcast and view the investor relations presentation, use the following webpage link:


During the presentations, the company will discuss business and financial developments and trends. The company’s statements may contain or constitute material information that has not been previously disclosed. For both events, listeners should allow approximately five to ten minutes prior to the presentations’ start times to visit the sites and download any streaming media software needed to listen to the Internet webcasts. Replays of both events will be archived on Quidel’s Web site at www.quidel.com under the “Events” section found within the Investor Relations portion of the site for 14 days following the live presentations. Quidel’s investor relations presentation will be posted under the “Presentations” section of the site.

About Quidel

Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue®, Quidel’s portfolio of products currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, respiratory syncytial virus, Fecal Occult Blood, Strep A, pregnancy, H. pylori and Chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel'sSpecialty Products Group (SPG) develops research products in the fields of oncology and bone health with potential future point-of-care applications. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment have an impact on clinical outcomes and provide an economic benefit. For more information, visit www.quidel.com, www.colorectal-test.com, www.rsvtesting.com and www.flutest.com.

Source: Quidel Corporation

Quidel Corporation
John M. Radak, Chief Financial Officer
Porter Novelli Life Sciences
Pam Lord